Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Diabetologia
Published in: Diabetologia 1/2004

01-01-2004 | Comment

—to: Looker HC, Fagot-Campagna A, Gunter EW et al. (2003) Homocysteine as a risk factor for nephropathy and retinopathy in Type 2 diabetes. Diabetologia 46:766–772

Authors: N. Shukla, G. D. Angelini, Dr. Jamie Y. Jeremy

Published in: Diabetologia | Issue 1/2004

Login to get access

Excerpt

To the Editor: We read with interest the recent paper by Looker et al. [1] who presented a study on homocysteine as a risk factor for nephropathy and retinopathy in Type 2 diabetes. We would like to add some comments and observations relating to possible underlying mechanisms that may be of interest. …
Literature
1.
Looker HC, Fagot-Campagna A, Gunter EW et al. (2003) Homocysteine as a risk factor for nephropathy and retinopathy in Type 2 diabetes. Diabetologia 46:766–772CrossRefPubMed
2.
Shukla N, Thompson CS, Angelini GD, Mikhailidis DP, Jeremy JY (2002) Homocysteine augments the reduction of endothelium dependent relaxation and cGMP formation in diabetic rabbits. Diabetologia 45:1325–1331CrossRef
3.
Jeremy JY, Shukla N, Angelini GD (2002) Homocysteine and cardiovascular disease in diabetes. Atherosclerosis 164:383–384CrossRefPubMed
4.
Emsley A, Jeremy JY, Gomes G, Angelini GD, Plane F (1999) Copper interacts with homocysteine to inhibit nitric oxide formation in the rat isolated aorta. Br J Pharmacol 126:1034–1040PubMed
5.
Emsley A, Plane F, Miller A, Jackson CL, Jeremy JY (1998) Homocysteine, oxidant stress and vascular disease. Vasc Dis 1:3–8
6.
Mansoor MA, Bergmark CB, Haswell SJ, Savage IF, Evans PH, Berge RK, Svardal AM, Kristensen O (2000) Correlation between plasma total homocysteine and copper in patients with peripheral vascular disease. Clin Chem 46:385–391PubMed
7.
Shukla N, Marshman N, Emsley AM, Taberner P, Jeremy JY (2001) Copper augments impaired endothelium-dependent relaxation of the aorta of the diabetic rabbit. Fund Clin Pharmacol 49:7P224 (Abstract)
Metadata
Title
—to: Looker HC, Fagot-Campagna A, Gunter EW et al. (2003) Homocysteine as a risk factor for nephropathy and retinopathy in Type 2 diabetes. Diabetologia 46:766–772
Authors
N. Shukla
G. D. Angelini
Dr. Jamie Y. Jeremy
Publication date
01-01-2004
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 1/2004
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-003-1259-5

Other articles of this Issue 1/2004

Diabetologia 1/2004 Go to the issue

Erratum

Erratum to: Characterisation of new KATP-channel mutations associated with congenital hyperinsulinism in the Finnish population

Article

Stable transplantation results of magnetically retracted islets: a novel method

Erratum

Loss of beta-cell mass leads to a reduction of pulse mass with normal periodicity, regularity and entrainment of pulsatile insulin secretion in Göttingen minipigs

Letter

Authors’ reply

Observation

Ethnicity, body mass index and diabetes

Article

Birthweight of offspring and paternal insulin resistance and paternal diabetes in late adulthood: cross sectional survey
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits